Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jonathan W. Riess, Julia Rotow et al.|JTO Clinical and Research Reports|2023Cited by 39
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.Jingran Ji, Jonathan W. Riess, Jacqueline V. Aredo et al.|Journal of Clinical Oncology|2020Cited by 18